natgillin/translations-raw huggingface dataset:
Zoledronic Acid Hospira works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zoledronatna kiselina djeluje tako sto vraća proces preoblikovanja kosti u normalu, osiguravajući stvaranje normalne kosti, čime kosti postaju snažnije.
Zoledronic Acid Hospira, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu Hospira, dodatno razrijeđenu u 100 ml (vidjeti dio 6.6), treba primjeniti kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid is contraindicated during pregnancy (see section 4.3).
Zoledronatna kiselina je kontraindicirana tijekom trudnoće (vidjeti dio 4.3).
Zoledronic acid is contraindicated in breast-feeding women (see section 4.3).
Zoledronatna kiselina kontraindicirana je u dojilja (vidjeti dio 4.3).
Zoledronic acid is contraindicated in patients with creatinine clearance < 35 ml/min (see sections 4.3 and 4.4).
Zoledronatna kiselina je kontraindicirana u bolesnika s klirensom kreatinina < 35 ml/min (vidjeti dio 4.3 i 4.4).
Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely.
Zoledronatna kiselina se ne veže u nekoj zamjetnoj mjeri za proteine plazme (približno 43-55% vezanja) stoga nisu vjerojatne interkacije zbog preraspodjele lijeka koji se veže za proteine u znatnoj mjeri.
Zoledronic acid is not metabolised and is excreted unchanged via the kidney.
Zoledronatna kiselina se ne metabolizira te se izlučuje u nepromijenjenom obliku preko bubrega.
Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zoledronatna kiselina ne preporučuje se za bolesnike koji prije početka terapije imaju teško oštećenje bubrega koje se za ovu populaciju definira kao klirens kreatinina < 30 ml/min.
Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zoledronatna kiselina se ne preporučuje u bolesnika koji prije početka liječenja imaju teško oštećenje funkcije bubrega, koje se u ove populacije definira kao klirens kreatinina manji od 30 ml/min.
Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zoledronatna kiselina se ne preporučuje za bolesnike koje prije početka tarapije imaju teško oštećenje bubrega koje se zaovu populaciju definira kao klirens kreatinina < 30 ml/min.
Zoledronic acid is not recommended in women of childbearing potential.
Zoledronatna kiselina ne preporučuje se ženama reproduktivne dobi.
Zoledronic acid is not recommended in women of childbearing potential.
Zoledronatna kiselina se ne proporuča ženama u generativnoj dobi.
Zoledronic acid is not systemically metabolised and does not affect human cytochrome P450 enzymes in vitro (see section 5.2).
Zoledronatna kiselina se sistemski ne metabolizira i ne utječe na humane enzime citokroma P450 in vitro (vidjeti dio 5.2).
Zoledronic acid medac 4 mg/100 ml solution for infusion
Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju
Zoledronic acid medac 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju može se odmah primijeniti bez dodatne pripreme kod bolesnika s normalnom funkcijom bubrega.
Zoledronic acid medac 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju sadrži 4 mg zoledronatne kiseline u 100 ml otopine za infuziju za neposrednu primjenu u bolesnika s normalnom funkcijom bubrega.
Zoledronic acid medac 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju zoledronatna kiselina
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Zoledronatna kiselina medac 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronatna kiselina medac 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu medac 4 mg/5 ml koncentrat za otopinu za infuziju, dodatno razrijeđenu u 100 ml (vidjeti dio 6.6), treba dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid medac 4mg/100ml solution for infusion
Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju
Zoledronic acid medac 4mg/5ml concentrate for solution for infusion
Zoledronatna kiselina medac 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic acid medac can be given to people aged 65 years and over.
Zoledronatna kiselina medac može se davati osobama u dobi od 65 ili više godina.
Zoledronic acid medac is supplied as a concentrate for solution for infusion in a 5 ml plastic vial made of clear, colourless plastic (cycloolefine copolymer) with rubber stopper (type I bromobutyl) and sealed with flip-off seal (aluminium and polypropylene).
Zoledronatna kiselina medac isporučuje se kao koncentrat za otopinu za infuziju u plastičnoj bočici od 5 ml napravljenoj od prozirne, bezbojne plastike (cikloolefinski kopolimer) s gumenim čepom (brombutil tipa I) i zatvorenoj „flip-off“ poklopcem (od aluminija i polipropilena).
Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Zoledronatna kiselina medac isporučuje se u pakiranjima koja sadrže 1 bocu ili višestrukim pakiranjima s 4 ili 10 pakiranja od kojih svako sadrži 1 bocu.
Zoledronic acid medac is supplied as solution for infusion in a 100 ml colourless glass bottle (type I) with rubber stoppers (halobutyl, fluoropolymer coated) and aluminium flip-off caps.
Zoledronatna kiselina medac isporučuje se kao otopina za infuziju u boci od bezbojnog stakla (tipa I) s gumenim čepom (halobutilni, obložen fluoropolimerom) i aluminijskim poklopcem.
Zoledronic acid medac is supplied as unit packs containing 1 vial or 4 vials and as multipacks of 4 or 10 packs each containing 1 vial.
Zoledronatna kiselina medac isporučuje se u pojedinačnim pakiranjima koja sadrže 1 bočicu ili 4 bočice i u višestrukim pakiranja od 4 ili 10 pakiranja od kojih svako sadrži 1 bočicu.
Zoledronic acid medac must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina medac ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zoledronic acid medac must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu medac smije davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic acid medac must only be prescribed and administered to patients by health care professionals experienced in the administration of intravenous bisphosphonates.
Zoledronatnu kiselinu medac bolesnicima smiju propisivati i primjenjivati samo liječnici s iskustvom u intravenskoj primjeni bisfosfonata.
Zoledronic acid medac must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronatnu kiselinu medac bolesnicima smiju propisivati i primjenjivati samo liječnici s iskustvom u intravenskoj primjeni bisfosfonata.
Zoledronic acid medac treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje Zoledronatnom kiselinom medac smije se nastaviti istom dozom koja se davala prije prekida liječenja.
Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu smiju davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu Teva smiju davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic acid must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronatnu kiselinu Hospira bolesnicima smiju propisivati i primjenjivati samo zdravstveni djelatnici s iskustvom u intravenskoj primjeni bisfosfonata.
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion
Zoledronatna kiselina Mylan 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrat Zoledronatne kiseline Mylan ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione kao što je otopina Ringerovog laktata, te se mora primijeniti kao zasebna intravenska otopina putem zasebne infuzijske linije.
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrat Zoledronatne kiseline Mylan ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina putem zasebnog infuzijskog sustava.
Zoledronic acid Mylan contains sodium.
Zoledronatna kiselina Mylan sadrži natrij
Zoledronic acid Mylan contains the same active substance as found in medicinal products indicated for treatment of osteoporosis and Paget´s disease of the bone.
Zoledronatna kiselina Mylan sadrži istu djelatnu tvar djelatnu tvar kao i lijekovi indicirani za liječenje osteoporoze i Pagetove bolesti kostiju.
Zoledronic acid Mylan is a clear and colourless concentrate for solution for infusion.
Zoledronatna kiselina Mylan je bistar i bezbojni koncentrat za otopinu za infuziju.
Zoledronic acid Mylan must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu Mylan smije davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic acid recommended dose*
Preporučena doza zoledronatne kiseline
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Potreban je oprez kad se zoledronatna kiselina primjenjuje zajedno s drugim lijekovima koji mogu utjecati na bubrežnu funkciju (vidjeti dio 4.5).
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
zoledronatnu kiselinu treba primijeniti s oprezom kada se istodobno daje s drugim lijekovima koji mogu oštetiti funkciju bubrega (vidjeti dio 4.5)
Zoledronic acid should only be resumed when serum creatinine returns to within 10 % of baseline.
S primjenom zoledronatne kiseline smije se nastaviti tek kad se kreatinin u serumu vrati na vrijednosti unutar 10% početne vrijednosti (vidjeti dio 4.2).
Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline.
S primjenom zoledronatne kiseline smije se nastaviti tek kad se kreatinin u serumu vrati na vrijednosti unutar 10% početne vrijednosti .
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56 %) and independent of the concentration of zoledronic acid.
Zoledronatna kiselina ne pokazuje afinitet za krvne stanice, a vezanje za proteine plazme je nisko (približno 56%) i ne ovisi o koncentraciji zoledronatne kiseline.
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.
Zoledronatna kiselina ne pokazuje afinitet za krvne stanice, a vezanje za proteine plazme je nisko (približno 56%) i ne ovisi o koncentraciji zoledronatne kiseline.
Zoledronic acid significantly reduced the mean days of limited activity by 17.9 days compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p<0.01).
Zoledronatna kiselina značajno je smanjila srednju vrijednost broja dana s ograničenom aktivnošću za 17,9 dana u usporedbi s placebom, odnosno srednju vrijednost broja dana s ograničenom aktivnošću zbog prijeloma za 2,9 i broja dana provedenih u krevetu zbog prijeloma za 0,5 dana u odnosu na placebo (za sve p<0,01).
Zoledronic acid Teva 4 mg/100 ml solution for infusion
Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju
Zoledronic acid Teva 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju može se odmah primijeniti bez dodatne pripreme kod bolesnika s normalnom funkcijom bubrega.
Zoledronic acid Teva 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju sadrži 4 mg zoledronatne kiseline u 100 ml otopine za infuziju za neposrednu primjenu u bolesnika s normalnom funkcijom bubrega.
Zoledronic acid Teva 4 mg/100 ml solution for infusion must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju ne smije se miješati s drugim otopinama za infuziju i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zoledronic acid Teva 4 mg/100 ml solution for infusion should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu Teva 4 mg/100 ml otopinu za infuziju treba dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid Teva 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju zoledronatna kiselina
Zoledronic Acid Teva 4 mg/5 ml concentrate for solution for infusion
Zoledronatna kiselina Teva 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic acid Teva 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu Teva 4 mg/5 ml koncentrat za otopinu za infuziju, dodatno razrijeđenu u 100 ml (vidjeti dio 6.6), treba dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid Teva 4mg/5ml concentrate for solution for infusion and Zoledronic acid teva 4mg/100ml solution for infusion
Zoledronatna kiselina Teva 4 mg/5 ml koncentrat za otopinu za infuziju i Zoledronatna kiselina Teva 4 mg/100 ml otopina za infuziju
Zoledronic Acid Teva 4mg/5ml concentrate for solution for infusion only
Zoledronatna kiselina Teva 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic Acid Teva can be given to people aged 65 years and over.
Zoledronatna kiselina Teva može se davati osobama u dobi od 65 ili više godina.
Zoledronic Acid Teva concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina Teva ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je Ringerova otopina s laktatom, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zoledronic acid Teva contains 15.6 mmol (or 359.6 mg) sodium per dose.
Zoledronatna kiselina Teva sadrži 15,6 mmol (ili 359,6 mg) natrija po dozi.
Zoledronic acid Teva contains 15.6 mmol (or 359.6 mg) sodium per vial
Zoledronatna kiselina Teva sadrži 15,6 mmol (ili 359,6 mg) natrija po bočici
Zoledronic acid Teva Generics
Zoledronatna kiselina Teva Generics
Zoledronic acid Teva Generics 5 mg solution for infusion in bags
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju u vrećicama
Zoledronic acid Teva Generics 5 mg solution for infusion in bags is ready for use.
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju u vrećicama je spremna za uporabu.
Zoledronic acid Teva Generics 5 mg solution for infusion in bags zoledronic acid
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju u vrećicama zoledronatna kiselina
Zoledronic acid Teva Generics 5 mg solution for infusion in bottles
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju u bočicama
Zoledronic acid Teva Generics 5 mg solution for infusion is ready for use.
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju je spremna za uporabu.
Zoledronic acid Teva Generics 5 mg solution for infusion zoledronic acid
Zoledronatna kiselina Teva Generics 5 mg otopina za infuziju zoledronatna kiselina
Zoledronic acid Teva Generics contains sodium
Zoledronatna kiselina Teva Generics sadrži natrij
Zoledronic acid Teva Generics contains the active substance zoledronic acid.
Zoledronatna kiselina Teva Generics sadrži djelatnu tvar zoledronatnu kiselinu.
Zoledronic acid Teva Generics has no or negligible influence on the abililty to drive and use machines.
Zoledronatna kiselina Teva Generics ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Zoledronic acid Teva Generics is a clear and colourless solution for infusion.
Zoledronatna kiselina Teva Generics je bistra i bezbojna otopina za infuziju.
Zoledronic acid Teva Generics is a ‘generic medicine’.
Zoledronatna kiselina Teva Generics je „generički lijek”.
Zoledronic acid Teva Generics is also used to treat Paget’s disease of the bone in adults.
Zoledronatna kiselina Teva Generics koristi se također za liječenje Pagetove bolesti kostiju u odraslih osoba.
Zoledronic acid Teva Generics may also cause other side effects
Zoledronatna kiselina Teva Generics može uzrokovati i druge nuspojave
Zoledronic acid Teva Generics should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Potreban je oprez kad se Zoledronatna kiselina Teva Generics primjenjuje zajedno s drugim lijekovima koji mogu utjecati na bubrežnu funkciju (vidjeti dio 4.5).
Zoledronic acid Teva Generics with food and drink
Zoledronatna kiselina Teva Generics s hranom i pićem
Zoledronic acid Teva is a ‘generic medicine’.
Zoledronatna kiselina Teva je „generički lijek”.
Zoledronic Acid Teva is supplied as a concentrate for solution for infusion.
Zoledronatna kiselina Teva isporučuje se kao koncentrat za otopinu za infuziju.
Zoledronic acid Teva is supplied as a solution for infusion.
Zoledronatna kiselina Teva isporučuje se kao otopina za infuziju.
Zoledronic acid Teva is supplied as packs containing 1, 4 or 10 bottles.
Zoledronatna kiselina Teva isporučuje se u pakiranjima od 1, 4 ili 10 boca.
Zoledronic acid Teva Pharma (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate.
Zoledronatna kiselina Teva Pharma (5 mg u 100 ml otopine spremne za infuziju) primjenjuje se putem infuzijske cjevčice s odzračivanjem uz konstantnu brzinu infuzije.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju u vrećicama
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags is ready for use.
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju u vrećicama je spremna za uporabu.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju u bočicama
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles zoledronic acid
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju u bočicama zoledronatna kiselina
Zoledronic acid Teva Pharma 5 mg solution for infusion is ready for use.
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju je spremna za uporabu.
Zoledronic acid Teva Pharma 5 mg solution for infusion zoledronic acid
Zoledronatna kiselina Teva Pharma 5 mg otopina za infuziju zoledronatna kiselina
Zoledronic acid Teva Pharma contains sodium
Zoledronatna kiselina Teva Pharma sadrži natrij
Zoledronic acid Teva Pharma contains the same active substance found in Zometa (zoledronic acid), used for oncology indications, and a patient being treated with Zometa should be not be treated with Zoledronic acid Teva Pharma.
Zoledronatna kiselina Teva Pharma sadrži istu djelatnu tvar kao i Zometa (zoledronatna kiselina), koja se koristi za onkološke indikacije, pa se bolesnici koji se liječe Zometom ne smiju liječiti Zoledronatnom kiselinom Teva Pharma.
Zoledronic acid Teva Pharma contains the same active substance found in Zometa (zoledronic acid), used for oncology indications, and a patient being treated with Zometa should not be treated with Zoledronic acid Teva Pharma.
Zoledronatna kiselina Teva Pharma sadrži istu djelatnu tvar kao i Zometa (zoledronatna kiselina), koja se koristi za onkološke indikacije, pa se bolesnici koji se liječe Zometom ne smiju liječiti Zoledronatnom kiselinom Teva Pharma.
Zoledronic acid Teva Pharma has no or negligible influence on the ability to drive and use machines.
Zoledronatna kiselina Teva Pharma ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Zoledronic acid Teva Pharma is a clear and colourless solution.
Zoledronatna kiselina Teva Pharma je bistra i bezbojna otopina.
Zoledronic acid Teva Pharma is a ‘generic medicine’.
Zoledronatna kiselina Teva Pharma je „generički lijek”.
Zoledronic acid Teva Pharma is also used to treat Paget’s disease of the bone in adults.
Zoledronatna kiselina Teva Pharma se također koristi za liječenje Pagetove bolesti kostiju kod odraslih osoba.
Zoledronic acid Teva Pharma is not recommended in women of childbearing potential.
Zoledronatna kiselina Teva Pharma ne preporuča se ženama reproduktivne dobi.
Zoledronic acid Teva Pharma is supplied in multipacks containing 5 or 10 bags (5 bags of 100 ml or 10 bags of 100 ml).
Zoledronatna kiselina Teva Pharma dostupna je u višestrukim pakiranjima sa 5 ili 10 vrećica (5 vrećica od 100 ml ili 10 vrećica od 100 ml).
Zoledronic acid Teva Pharma is supplied in packs of 1, 5 or 10 bottles.
Zoledronatna kiselina Teva Pharma dostupna je u pakiranjima sa 1, 5 ili 10 bočica.
Zoledronic acid Teva Pharma may also cause other side effects
Zoledronatna kiselina Teva Pharma može uzrokovati i druge nuspojave
Zoledronic acid Teva Pharma should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Potreban je oprez kad se Zoledronatna kiselina Teva Pharma primjenjuje zajedno s drugim lijekovima koji mogu utjecati na bubrežnu funkciju (vidjeti dio 4.5).
Zoledronic acid Teva Pharma with food and drink
Zoledronatna kiselina Teva Pharma s hranom i pićem